1. INTRODUCTION {#S5}
===============

Tea, one of the most widely consumed beverages worldwide, is derived from young buds and the leaves of several varieties of *Camellia sinensis* (Theaceae), first cultivated in China and Southeast Asia over 2,000 years ago \[[@R1]\]. The three major types of tea are green, oolong, and black. Oolong tea, upon which this paper is based, represents an intermediate in the preparation of green and black teas. Green tea is prepared by initial heating (pan firing or steaming) to inactivate the endogenous enzymes, while oolong and black teas are said to be 'fermented,' that is, after moisture reduction (a process termed withering), the leaves are rolled and crushed, a procedure that begins the endogenous enzymatic reactions. Oolong tea is fired soon after crushing to inactivate these reactions, while black tea is prepared after increased 'fermentation.' Oolong tea, like the green and black teas, is composed primarily of the four polyphenolic catechins, epigallocatechin gallate (EGCG), epigallate catechin, epicatechin gallate, and epicatechin, with EGCG being the most prevalent. While there are many studies on green tea, the literature on oolong tea is less detailed. There is an indication that oolong tea may contain several unique components resulting from the fermentation protocol, i.e. oolongtheanin, 8-ascorbyl EGCG, and oolonghomobisflavans \[[@R1]\], but no suggestions of physiological effects have been attributed to these products.

In addition to its popularity as a beverage, tea has been reported to have many beneficial effects to human health, including a reduction in the incidence of cancer and cardiovascular disease \[[@R2]--[@R7]\] as well as suggestions that tea may reduce the possibility of ischemic stroke \[[@R8]--[@R11]\]. Further, it has been shown that oolong tea is more effective than black tea, although less effective than green tea, in inhibiting an important enzyme in blood pressure regulation, angiotensin converting enzyme \[[@R12]\]. These reports notwithstanding, caution has been suggested in recommending tea to the population at large or to individual patients to lower cardiovascular risks \[[@R13]\]. Although there are some indications of adverse effects from concentrated green tea extracts, including liver toxicity and interactions with drugs and herbal supplements \[[@R14]\], there are no reported symptomatic responses to oolong, green, or black tea similar to those detailed in the present case study.

There are many neurologic symptoms accompanying a transient ischemic attack (TIA), and the etiology can be diverse, including hypertension, atrial fibrillation, hypercholesterolimia, diabetes, increasing age, and a family history of stroke. A TIA arises from ischemia, most often from an embolus originating in an atherosclerotic plaque in one of the carotid arteries or from a thrombus in someone with atrial fibrillation. Indicative of a possible future stroke, preventive action should be taken to minimize such an occurrence. Since atrial fibrillation is one of the factors responsible for a TIA, an anticoagulant such as warfarin or one of the newer anti-coagulants is often prescribed for such patients. Warfarin exerts its action on the vitamin K-dependent clotting factors, in particular by inhibiting the essential enzyme, vitamin K epoxide reductase complex 1 (VKORC1), that acts in the vitamin K cycle to catalyze the reduction of vitamin K epoxide to vitamin K quinone, thus diminishing the carboxylation of factors II, VII, IX, X, and the C and S anticoagulant proteins \[[@R15],[@R16]\].

The case presented in this study is suggestive of a possible effect of concentrated oolong tea producing some TIA-like symptoms that, to the best of our knowledge, have not been reported before.

2. PRESENTATION OF CASE {#S6}
=======================

2.1 Evaluation by an Emergency Care Physician {#S7}
---------------------------------------------

The patient, a 72 year-old Caucasian male in good physical condition, presented at the emergency department of a local hospital describing neurologic symptoms that had occurred about two hours earlier and were indicative of a TIA. He reported that while speaking with someone in his office as he finished drinking a cup of oolong tea he developed a number of worrisome symptoms. The patient had consumed a cup of green or oolong tea daily for many years prior to this incident, the usual amount being approximately 250 mg (dry weight of tea leaves) per 240 mL hot water. On this particular day the tea was prepared in a more concentrated blend, about 4--5 times the usual (1--1.2 g dry weight per 240 mL), seeped five minutes, the leaves remaining in the cup during the 30 min period of consumption. Immediately upon finishing the cup of tea, he experienced the following indicators of a TIA: mild visual problems (symptoms not descriptive, however, of presbyopia or amaurosis fugax), presyncope, disequilibrium, hand parathesias (albeit bilateral), and following that meeting noticed some mild dysphasia when speaking with someone else. He also noted that he had experienced some presyncope in the past when consuming either a greater quantity or a more concentrated Japanese green tea at a local restaurant. The symptoms had disappeared upon presentation at the hospital, but there was sufficient concern on the part of the patient, his wife, and attending physician that they felt an evaluation was needed in view of his past medical history. He had been diagnosed with hypertension and benign prostatic hypertrophy, and five years earlier with atrial flutter. The flutter was corrected by cardiac ablation in the right atrium, with atrial fibrillation one year earlier. His daily medications were warfarin sodium (coumadin, 5 mg six days a week and 7.5 mg once a week), taken in the evening about 9:00 PM, and valsartan/hydrochlorothiazide (diovan/HCTZ, 160 mg/12.5 mg), alfuzosin HCI (uroxatral, 10 mg), rebeprazole sodium (aciphex, 20 mg for acid reflux), and bifidobacterium infantis (probiotic, 4 mg), all taken in the early morning between 5:00--6:00 AM. He was alert and had a temperature of 97.3°F, a pulse rate of 57 beats per minute, a systolic/diastolic blood pressure of 160/90 that later decreased to 139--141/80--76 mm Hg during his stay in the emergency department, and an oxygen saturation of 97--99% throughout his stay as an outpatient. He mentioned that his blood pressure had been treated for several years and was generally lower than that measured in the hospital setting. Laboratory tests were mainly in the normal range, with a few being either marginally low or high. The prothrombin and partial thromboplastin times were elevated (22.5 and 39 sec, respectively), and the prothrombin time-international reference (PT-INR) was 2.0, attributable to warfarin. An x-ray of the chest demonstrated that the lungs were clear bilaterally and the cardiac silhouette and mediastinum were unremarkable; CT of the brain (axial imaging) showed no evidence of an acute process. Heart irregularity was noted, and an electrocardiogram (EKG) revealed atrial fibrillation with an average rate in the 50s, a normal axis, and no evidence of ST segment abnormalities. The patient was administered IV fluid and then released with a recommendation that he see a cardiologist for further evaluation.

2.2 Evaluation by a Cardiologist {#S8}
--------------------------------

A physical examination by the cardiologist demonstrated an irregularly irregular rhythm, consistent with the patient's known atrial fibrillation, but no abnormalities. The carotids were full and equal bilaterally without bruits; the neck veins were normal with no elevation of the jugular venous pressure. The conclusions from a 2D transthoracic echocardiogram (TTE) using color and doppler flow imaging were as follows: there was mild right atrial enlargement with mild to moderate tricuspid insufficiency; the estimated right ventricular systolic pressure was slightly elevated; the left and right ventricles appeared normal in size, and the left ventricular systolic and diastolic function appeared normal; the aortic valve showed mild sclerosis without evidence of stenosis; and the mitral valve was structurally normal. An agitated saline contrast image ('bubble study') showed no evidence of an intracardiac shunt. It was recommended that the patient begin 81 mg aspirin to be taken 3 times a week, along with warfarin. Overall there was no evidence of serious cardiac problems other than atrial fibrillation. In view of the TIA-like symptoms the patient originally presented with, it was suggested that he also be examined by a neurologist.

2.3 Evaluation by a Neurologist {#S9}
-------------------------------

A brain magnetic resonance imaging (MRI), with and without 20 ml Gadolinium, and a magnetic resonance angiogram (MRA) yielded the following information. The diffusion-weighted images were negative, and gradient echo studies showed no evidence for a prior hemorrhage. Overall, no acute intracranial abnormality was observed, and, importantly, there was no evidence for a prior cortically-based infarct; moreover, after Gadolinium administration a normal meningeal and vascular enhancement was observed. There was evidence of minimal small vessel ischemic cerebrovascular changes in the hemispheres, some slight fluid accumulation within the mastoid air cells, and mucosal lining thickening in the inferior maxillary sinuses and a few of the ethmoidal air cells. The MRA documented the absence of any hemodynamically significant stenosis involving the arteries of the neck.

2.4 Summary {#S10}
-----------

A brain CT and MRI failed to detect any evidence of an infarct, and a MRA of the neck indicated normal flow. The 2D TTE of the heart, with and without agitated saline to ascertain bubble passage, detected no abnormality. Thus, atrial fibrillation appeared to be the only significant problem of the patient.

Based on these medical results, a study was undertaken to characterize the oolong tea that was consumed and, although there is no known precedent in the literature, could possibly have led to the acute TIA-like symptoms experienced by the patient. The goal was to determine the constituents in the tea, after extraction in hot water as was done for consumption. The techniques employed were liquid chromatography tandem mass spectrometry (LC-MS/MS) and high performance liquid chromatography (HPLC) using conditions similar to those described by others \[[@R17]--[@R20]\]. The methodologies used and the experimental data are reported in the [Appendix](#APP1){ref-type="app"}.

3. RESULTS AND DISCUSSION {#S11}
=========================

Selected MS/MS spectra of the oolong tea extract are presented as examples in Appendix Fig. 1. [Fig. 1A](#F1){ref-type="fig"} shows the MS/MS spectrum of EGCG analyzed in negative ion mode at m/z 457 (eluted at 12.55 min). The mass-to-charge ratios (m/z) of the main fragment ions observed were 168.9 and m/z 305, corresponding to gallic acid and epigallocatechin, respectively. Also, EGCG showed a neutral loss of trihydroxybenzene at m/z 331. The MS/MS spectrum of quercetin 3-O-glucosylrutinoside at m/z 771 (eluted at 16.87 min) is given in [Fig. 1B](#F1){ref-type="fig"}. The main fragment ion (m/z 301) corresponds to quercetin, confirming the structure of the flavonoid moiety in the parent ion. A neutral loss of the carbohydrate portion was found at m/z 349 and m/z 609. The m/z 349 component is attributed to a cross-ring cleavage of the hexose attached on quercetin at the 1 and 3 carbon bonds (1,3A/1,3X), whereas m/z 609 results from a neutral loss of the terminal hexose. This fragmentation pattern confirmed the structure of the carbohydrate moiety in the parent ion. A few flavonoids, including caffeine, were detected in just the positive ion mode because of their polarity. Also, in the positive ion mode acylated flavonol glycosides were observed in the H^+^, Na^+^, and K^+^ forms. For MS/MS analysis of the acylated flavonol glycosides in the positive ion mode, the H^+^ form caused ion suppression during MS/MS fragmentation that resulted in poor signals; in these cases structural assignments were based on the Na^+^ adducts. The flavonoids identified in the tea sample are given in [Appendix Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} for results obtained in the negative and positive ion modes, respectively. For structural assignment the observed full mass and MS/MS were compared to those of known standards, those reported previously \[[@R18]--[@R20]\], and the theoretical full mass and MS/MS.

A sample of Yamamotoyama oolong tea was brewed according to the recommendations of the manufacturer, filtered, and then analyzed by MS. This control tea gave an almost identical profile to that of the oolong tea consumed by the patient, confirming that unusual or unexpected peaks were not present in the 'experimental' tea.

The HPLC chromatograms of the oolong tea extract are shown in [Fig. 2](#F2){ref-type="fig"} with detection at 270 nm (panel A) and 350 nm (Panel B), and assignments of the major peaks. Caffeine and the catchenins, EGCG and epicatechin gallate, are the major components identified at 270 nm, and the major phenolic components identified at 350 nm are myricetin 3-O-galactoside, quercetin 3-O-glucosylrutinoside, quercetin rutinoside, and kaempferol 3-O-glucosylrutinoside; many other minor components are seen in each chromatogram.

The results obtained from MS and HPLC characterization of the oolong tea are in excellent agreement with findings reported by others \[[@R18]--[@R20]\], demonstrating the complexity and variety of components present in tea. A detailed study on 41 green teas and 25 fermented teas enabled Lin et al. to classify the teas into five categories based upon their compounds \[[@R18]\]. Oolong tea was in Group 3 that, compared to green tea, contained less EGCG, more theaflavins and other catechins, and comparable amounts of glycosylated flavonols. The majority of the health benefits attributed to tea are believed to arise from the flavonoids, particularly the catechins (polyphenols) that are the major constituent of tea. Present in much lower concentrations are the methylxanthines, including caffeine, theophylline, and methlyxanthine theobromine, the first two of which were detected in our sample. While caffeine, a well-known CNS and metabolic stimulant, may be suspect in leading to some of the TIA-like symptoms experienced by the patient, there is no documentation of such effects in the literature. Four caffeine-induced disorders are recognized by the American Psychiatric Association, none of which correspond to the symptomology of the patient discussed herein \[[@R21]\]. Interestingly, EGCG, the major catechin in tea and confirmed to be present in the tea in question in this study, has been suggested to counteract caffeine-mediated stimulant effects \[[@R22]\].

Although tea leaves contain 14.3 and 2.6 μg vitamin K/g dry leaves in green and black tea, respectively \[[@R23]\], relatively little is extracted by seepage in hot water \[[@R24]\]. There are, however, two reports implicating tea, and thus vitamin K, in patients taking warfarin. In one, a male began consuming a rather large quantity of green tea daily, 0.5--1.0 gallons, and experienced a reduction in his INR from 3.8 to 1.4 that was restored to 2.6 upon discontinuation of green tea \[[@R25]\]. In another, a woman had regularly drunk an undisclosed amount of black tea each day and maintained her INR between 2--3. Upon discontinuing consumption of black tea, her INR increased to 5.0 but was restored to the 2--3 range when her warfarin dose was decreased \[[@R26]\]. While suggesting that tea can alter the INR of some individuals taking warfarin, it was not an issue in the present case since the patient was found to have an INR of 2.0 when he presented at the hospital.

It is unlikely that the response to the tea could arise from an acute metabolic disturbance of one or more medicines being taken by the patient, or vice versa, particularly since the onset of the symptoms appeared immediately after drinking the tea while the medications had been taken anywhere from 7--15 hours earlier. There are reports in experimental animals that quercetin enhances the bioavailability of valsartan \[[@R27]\]; however, the patient described herein had taken his daily valsartan some seven hours before drinking the concentrated tea. In another report based on studies in human hepatoma HepG2 cells and primary cultures of human hepatocytes, the authors concluded that EGCG is an antagonist to the aryl hydrocarbon receptor that regulates the expression of the cytochrome (CYP) P450 subfamily CYP1A, composed of two members, CYP1A1 and CYP1A2, that metabolize many chemical carcinogens \[[@R28]\]. At present, there is no apparent correlation of this effect with any of the symptomology experienced by the patient. Additionally, genotypes of CYP2C8 and CYP2C9, cytochrome P450s responsible for the metabolism of most angiotensin II receptor antagonists, impact on the pharmacokinetics of valsartan \[[@R29]\], but the relationship of these findings to the patient presented is not known. Of interest are the reports indicating that tea may reduce the onset of stroke \[[@R8]--[@R11]\], thus strengthening our suggestion that the symptoms observed in the patient were, in many respects, TIA-like, not an actual TIA.

Since (a) atrial fibrillation significantly increases a person's risk of stroke or systemic embolization, with the risk steadily increasing with age, and (b) while warfarin reduces the risk some 62--68%, but does not eliminate it altogether, atrial fibrillation must be considered as a possible cause of a TIA in the patient. Moreover, brain and MR angiography imaging have known limitations, including (a) the ability to visualize some vessels but not others, and (b) the possibility that some microemboli could have been present but were too small to be imaged or the emboli may have broken up and resolved by the time the imaging was performed. On the other hand, the neurologic symptoms exhibited by the patient do not fit any cerebral vascular distribution involving, for example, a clot going to one area of the brain. In light of the fact that some of the symptoms were bilateral, e.g. hand parathesias, while others suggest a global cerebral process, e.g. presyncope, only a simultaneous diminished flow or pressure going to both sides of the brain could cause a similar picture, and this is ruled out by the normal or slightly elevated blood pressure of the patient in the Emergency Department. Thus, following a thorough evaluation of the patient and a critical review of the medical findings, no unequivocal evidence was found to indicate that a TIA had occurred, and it must be considered that the symptomology could be attributable to an unusual acute effect from the concentrated oolong tea.

4. CONCLUSIONS {#S12}
==============

A thorough medical evaluation revealed no indications of a TIA, or even an arterial territory syndrome, and no unexpected components were identified in the oolong tea by HPLC and LC-MS/MS. We suggest that concentrated oolong tea may, under certain conditions, lead to acute TIA-like effects. Such a response to tea is unusual, and it is not known if the symptomology described could arise from just one or several constituents of the tea. Moreover, it is not known whether or not there is an interaction of the oolong tea with one or more of the medications taken by the patient or if an unusual pharmacogenetic background of the patient could enhance any possible effect of the tea. While one could argue that tea-mediated hypotension could explain some of the symptoms experienced by the patient, there is no conclusive evidence that a drop in blood pressure could explain all the symptoms. Thus the effect may reflect both hemodynamic and CNS effects attributable to the oolong tea.

The authors thank Dr. Richard Panico for helpful discussions and suggestions. We also thank Dr. Gabriela Sanchez-Brambila for her assistance during the early phase of the experimental work. This research was supported in part by the National Institutes of Health (NIH/NCRR)-funded grant entitled 'Integrated Technology Resource for Biomedical Glycomics' (grant no. 8P41 GM103490) to the Complex Carbohydrate Research Center of the University of Georgia, Athens, Georgia, USA.

**Authors' contributions**

This work was carried out in collaboration between all authors. Author JWL evaluated the cardiological performance of the patient and made recommendations for the interpretation of the clinical results and revisions to the manuscript. Author JSP was responsible for the neurological evaluation of the patient and made suggestions regarding the case and revisions to the manuscript. Author MI performed the HPLC and MS experimental work, made peak assignments, and prepared the figures and tables. Author PA was responsible for the analytical services, including the choice of instrumentation and laboratory in which the experimental studies were performed, as well as ensuring proper interpretation of the results. Author GAM made the initial purification of the tea before HPLC and MS, and supervised the early MS studies. Author DP coordinated the overall study, interacted with all co-authors, performed extensive literature searches, and wrote the manuscript. All authors had the opportunity to read and revise the manuscript.

**CONSENT**

Written informed consent from the patient for publication of this case report copy was sent to the Chief Editor of this journal.

**ETHICAL APPROVAL**

Not applicable.

**COMPETING INTERESTS**

Authors declare that they have no competing interests.

CNS

:   central nervous system

CT

:   computerized tomography

CYP

:   cytochrome P450

EGCG

:   epigallocatechin gallate

EKG

:   electrocardiogram

HPLC

:   high performance liquid chromatography

INR

:   international normalized ratio (see PT-INR)

LC-MS/MS

:   liquid chromatography-tandem mass spectrometry

LTQ

:   linear trap quadropole

MS

:   mass spectrometry

MS/MS

:   tandem mass spectrometry

MRA

:   magnetic resonance angiogram

MRI

:   magnetic resonance imaging

m/z

:   mass-to-charge ratio

PT-INR

:   prothrombin time-international normalized ratio

TFA

:   trifluoroacetic acid

TIA

:   transient ischemic attack

TTE

:   transthoracic echocardiogram

VKORC1

:   vitamin K epoxide reductase complex 1

Preparation of the tea for LC-MS/MS and HPLC {#S15}
============================================

The oolong tea leaves (about 1.2 g of Tie Guan Yin Oolong Tea, Iron Goddess of Mercy, a high grade oolong tea) were seeped in 240 mL of hot water under conditions as close as possible to those used in the tea that was consumed (see Section 2.1). The leaves and any particulates were then separated from the liquid in the cup by filtration, and the filtrate was stored overnight at 5°C.

A SepPak cartridge (1 g) was inserted into a vacuum manifold and fitted with a 50 mL plastic syringe and then activated with 10 mL methanol (MeOH) and equilibrated with 20 mL 0.1% (trifluoroacetic acid (TFA). The tea extract (50 mL) was added, and the unbound components were eluted with 200 mL 0.1% TFA. Following transfer of the cartridge to a collection manifold, the non-polar compounds were eluted with 3 mL MeOH and then dried in a Speed-Vac. Next the sample was dissolved in 1 mL MeOH, dried, and reconstituted in a mixture of 0.9 mL 0.1% formic acid and 0.1 mL acetonitrile (CH~3~CN). Following heating at 50°C for about 5 min to ensure a homogeneous liquid phase, the sample was diluted 10-fold in 10% CH~3~CN in 0.1% formic acid.

LC-MS/MS {#S16}
========

Several MS runs were made using MALDI-TOF-MS (Bruker Autoflex) and LC-MS (Perkin-Elmer SC/EX), after which it was decided to use LC-MS/MS on a LTQ mass spectrometer (ThermoFisher) equipped with an electrospray ion source. Using conditions similar to those described for separating polyphenols \[[@R17]\], the sample was diluted 5-fold with mobile phase A (0.2% acetic acid in water) and filtered with 0.2 μm filters (Nanosep, PALL). 5 μL of the sample was injected into a C18 column (2.1 × 100 mm, Grace Vydac) followed by separation using a 60 min gradient of increasing mobile phase B (80% CH~3~CN and 0.2% acetic acid in water) at a flow rate of 200 μL/min.

The instrument was tuned with EGCG and caffeine for negative ion mode and positive ion mode, respectively. The LTQ was run in the automatic mode collecting a MS scan (full mass spectrometry at 150--2,000 m/z) followed by data-dependent MS/MS scans of the six highest abundant precursor ions. The data were analyzed manually for structural assignment, and the observed full mass and MS/MS were compared to those of known standards, e.g. EGCG and caffeine, those reported by others \[[@R18]--[@R20]\], and the theoretical full mass and MS/MS.

HPLC {#S17}
====

Analysis by HPLC was conducted to confirm the assignments made from LC-MS/MS and to check for the presence of any additional major peaks. The sample (10 μL) was injected into the same column used for LC-MS/MS and developed similarly. UV detection (Agilent Technologies) was at 270 nm and 370 nm, encompassing two separate runs. Using EGCG and caffeine as standards and the knowledge of components from LC-MS/MS, reports by others \[[@R18]--[@R20]\], and technical notes available from HPLC/MS companies, e.g. Agilent and Shimadsu, structural assignments were made.

![MS/MS spectra of oolong tea in the negative ion mode documenting the presence of EGCG, m/z 457 (A), and quercetin 3-O-glucosylrutinoside, m/z 771 (B). The main fragment ions identified in panel A are gallic acid (m/z 168.9) and epigallocatechin (m/z/305); the neutral loss of trihydroxybenzene is also indicated (m/z 331). In panel B the main fragment ion identified is quercetin (m/z 301). A neutral loss of the carbohydrate portion is indicated at m/z 349, arising from a cross-ring cleavage of quercetin at the 1 and 3 carbon bonds, and at m/z 609, attributed to a neutral loss of the terminal hexose](nihms578426f1){#F1}

![HPLC chromatograms of oolong tea monitored at 270 nm (A) and 350 nm (B). See Methods for experimental details, and the major peaks are identified](nihms578426f2){#F2}

###### 

Flavanoid analysis of oolong tea sample by LC-MS/MS in the negative ion mode

  RT      m/z    Proposed structure                                     MS/MS
  ------- ------ ------------------------------------------------------ ------------------------------------------------------------
  2.30    173    theamine                                               \-
  7.31    305    gallocatechin                                          179, 221, 261
  12.3    337    3-p-coumaroylquinic acid                               173, 191
  12.41   289    catechin                                               245
  12.44   305    epigallocatechin                                       287
  12.55   457    epigallocatechin gallate                               169, 331, 305
  13.34   337    5-p-coumaroylquinic acid                               173
  14.34   593    6,8 C-glycosylapigenin                                 473, 353, 503, 383, 575
  14.46   457    gallocatechin gallate                                  169, 331, 305
  14.64   337    4-p-coumaroylquinic acid                               191
  15.13   787    myricetin 3-O-galactosylrutinoside                     317 (M), 769, 625 (Loss of hex), 479 (Loss of hexdeoxyhex)
  15.31   479    myricetin 3-O-galactoside                              316, 317 (M)
  15.50   625    myricetin 3-O-rhamnosylglucoside                       316, 317 (M), 479 (Loss of deoxyhex)
  15.57   479    myricetin 3-O-glucoside                                316, 317 (M)
  15.68   563    apigenin 6-C-pentosyl-8-C-hexoside                     443, 473 (Loss of C-glycoside), 383, 353, 503, 545
  16.35   771    quercetin 3-O-galactosylrutinoside                     301 (Q), 609 (Loss of hex)
  16.65   593    \--                                                    413, 293
  16.87   771    quercetin 3-O-glucosylrutinoside                       301 (Q), 609 (Loss of hex)
  16.92   787    myricetin 3-O-galactosylrutinoside                     317 (M), 769, 625 (Loss of hex), 479 (Loss of hexdeoxyhex)
  17.13   609    quercetin-rhamnosylgalactoside                         301 (Q), 489
  17.36   463    quercetin 3-galactoside                                301 (Q)
  17.47   625    myricetin compound                                     317 (M), 607, 581
  17.47   609    quercetin-rutinoside                                   301 (Q)
  17.66   533    apigenin 6-C-pentosyl-8-C-pentoside                    443, 473 (Loss of C-glycoside), 383, 353, 515
  17.73   463    quercetin 3-glucoside                                  301 (Q)
  18.36   593    kaempferol 3-hexosyldeoxyhexoside                      285 (K), 255, 327 (hex2deoxyhex)
  18.47   755    kaempferol 3-O-glucosylrutinoside                      285 (K), 593 (Loss of hex)
  18.59   771    quercetin 3-O-hexosylrutinoside                        301 (Q), 609 (Loss of hex)
  18.81   447    kaempferol 3-O-galactoside                             284 (K), 327
  19.05   533    apigenin 6-C-pentosyl-8-C-pentoside                    443, 473 (Loss of C-glycoside), 383, 353, 515
  19.29   609    quercetin 3-O-deoxyhexosylhexoside                     301 (Q)
  19.33   593    kaempferol 3-hexosyldeoxyhexoside                      285 (K)
  19.33   625    myricetin compound                                     317 (M), 299, 607
  19.63   447    \--[a](#TFN1){ref-type="table-fn"}                     403, 249, 267
  20.18   417    kaempferol 3-O-pentoside                               284, 285 (K), 327
  24.08   1063   quercetin 3-O-acylglycoside                            917 (Loss of coumaric acid), 771, 615, 447, 301 (Q)
  24.47   917    quercetin 3-O-p-coumaroylhexosyldeoxyhexosylhexoside   771 (Loss of coumaric acid), 301 (Q)
  24.49   1063   myricetin 3-O-acylglycoside                            917 (Loss of deoxy-hex), 777, 317 (M)
  24.63   1049   quercetin 3-O-acylglycoside                            903 (Loss of coumaric acid), 301 (Q)
  24.71   917    quercetin 3-O-p-coumaroylhexosyldeoxyhexosylhexoside   771 (Loss of coumaric acid), 301 (Q)
  24.78   1033   quercetin 3-O-acylglycoside                            887 (Loss of coumaric acid), 741, 747, 447, 301 (Q)
  24.86   901    quercetin 3-O-p-coumaroylhexosyldeoxyhexosylhexoside   755 (Loss of coumaric acid), 609, 447, 301 (Q)
  25.00   1063   myricetin 3-O-acylglycoside                            917 (Loss of deoxy-hex), 741, 451, 317 (M)
  25.19   1049   quercetin 3-O-acylglycoside                            903 (Loss of coumaric acid), 301 (Q)
  25.41   1033   coumaric acid compound                                 887 (Loss of coumaric acid), 747, 597, 451
  25.59   1063   quercetin 3-O-acylglycoside                            917 (Loss of deoxy-hex), 771, 615, 447, 356, 301 (Q)
  25.71   901    kaempferol 3-O-p-coumaroyldideoxyhexosylhexoside       755 (Loss of coumaric acid), 615, 433, 285 (K)
  25.78   917    quercetin 3-O-p-coumaroylhexosyldeoxyhexosylhexoside   771, 753 (Loss of coumaric acid), 301 (Q)
  25.86   1033   \--[a](#TFN1){ref-type="table-fn"}                     \--
  25.97   901    quercetin 3-O-p-coumaroylhexosyldeoxyhexosylhexoside   755 (Loss of coumaric acid), 615, 447, 301 (Q)
  26.56   901    kaempferol 3-O-p-coumaroyldideoxyhexosylhexoside       755 (Loss of coumaric acid), 615, 285(K)

Unknown.

Abbreviations: Hex, hexose; K, kaempferol; M, myricetin; Q, quercetin.

###### 

Flavonoid analysis of oolong tea sample by LC-MS/MS in the positive ion mode

  RT      m/z             Proposed structure                                      MS/MS
  ------- --------------- ------------------------------------------------------- ----------------------------------------------
  1.54    175             theamine                                                \--
  1.86    181             theophylline                                            137, 138
  4.87    307             gallocatechin                                           139, 151, 289 (Loss of OH)
  8.47    195             caffeine                                                138
  11.98   291             catechin                                                123, 139
  12.28   459             epigallocatechin gallate                                139, 151, 289
  13.04   339             4-p-coumaroylquinic acid                                147
  14.14   595             6,8 C-glycosylapigenin                                  457 (Loss of C-hexo-side)
  14.30   459             gallocatechin gallate                                   139, 151, 289
  15.23   789             myricetin 3-O-galactosylrutinosode                      319 (M), 628, 482
  15.42   481             myricetin 3-O-galactoside                               319 (M)
  15.57   627             myricetin 3-O-rhamnosylglucoside                        319 (M), 481 (Loss of deoxyhex)
  15.60   481             myricetin 3-O-glucoside                                 319 (M), 313, 153, 171
  15.72   565             apigenin 6-C-pentosyl-8-C-hexoside                      547, 529, 428 (Loss of C-hexoside)
  16.31   773             quercetin 3-O-galactosylrutinoside                      303 (Q), 611, 465
  16.65   595             O-hexose+ C-hexosylapigenin                             433 (Loss of hexose)
  16.95   773             quercetin 3-O-glucosylrutinoside                        303 (Q), 611, 465
  17.10   611             quercetin-rhamnosylgalactoside                          303 (Q), 465
  17.14   579             O-deoxyhex+ C-hexosylapigenin                           433 (Loss of deoxy-hex)
  17.32   465             quercetin 3-galactoside                                 303 (Q)
  17.44   611             quercetin-rutinoside                                    303 (Q), 465
  17.52   579             O-deoxyhex+ C-hexosylapigenin                           433 (Loss of deoxy-hex)
  17.63   535             apigenin 6-C-pentosyl-8-C-pentoside                     517, 499, 481, 469
  17.70   465             quercetin 3-glucoside                                   303 (Q)
  18.37   595             kaempferol 3-hexosyldeoxyhexoside                       287 (K)
  18.52   757             kaempferol 3-O-glucosylrutinoside                       287 (K)
  18.78   449             kaempferol 3-O-galactoside                              287 (K)
  19.04   535             apigenin 6-C-pentosyl-8-C-pentoside                     517, 499, 481, 403, 385, 367
  19.26   595             kaempferol 3-hexosyldeoxyhexoside                       287 (K)
  19.59   449             kaempferol 3-O-hexoside                                 287 (K)
  20.04   419             kaempferol 3-O-pentoside                                287 (K)
  23.68   1065 (*1086*)   quercetin 3-O-acylglycoside                             *941, 785* (Loss of Q), *639, 493, 331*
  24.10   1065 (*1086*)   quercetin 3-O-acylglycoside                             *942, 787* (Loss of Q), *771, 640, 475, 330*
  24.25   1051 (*1073*)   quercetin 3-O-acylglycoside                             *771* (Loss of Q), *639, 607, 475*
  24.37   919 (*941*)     quercetin 3-O-p-coumaroylhexosyldeoxyhexosylhexoside    *639* (Loss of Q), *475*
  24.48   903 (*925*)     kaempferol compound                                     *779, 477*
  24.60   1065 (*1086*)   kaempferol 3-O-acylglycoside                            *801* (Loss of K), *637, 621, 475, 391*
  24.79   1051 (*1073*)   quercetin 3-O-acylglycoside                             *771* (Loss of Q), *621, 607, 475*
  25.06   1035 (*1057*)   kaempferol 3-O-acylglycoside                            *771, 607, 475*
  25.25   1065 (*1086*)   kaempferol 3-O-acylglycoside                            *941, 801* (Loss of K), *639, 475, 331*
  25.32   903 (*925*)     kaempferol 3-O-p-coumaroylhexosyldeoxyhexosylhexoside   *639* (Loss of K), *475*
  25.36   919 (*941*)     quercetin 3-O-p-coumaroylhexosyldeoxyhexosylhexoside    *639* (Loss of Q), *475*

Unknown.

Abbreviations: Hex, hexose; K, kaempferol; M, myricetin; Q, quercetin; RT, retention time. MS/MS analysis of acyl glycosides (italicized) were performed on sodium adducts, and the m/z values are italicized in parentheses.
